Introduction
============

Non-small-cell lung cancer (NSCLC), accounting for more than 85% of lung cancer cases, is a leading cause of cancer-related death worldwide.[@b1-cmar-8-011] NSCLC usually presents with advanced stage at diagnosis. Conventional systemic chemotherapy, mainly platinum-based regimens, has been the cornerstone of treatment for advanced NSCLC, although it provides only a modest benefit in survival.[@b2-cmar-8-011] Increased knowledge of the molecular biology of lung cancer led to the development of the specific anti-*EGFR* tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. These targeted agents have shown a higher efficacy among patients harboring specific activating mutations in exons 18--21 encoding the tyrosine kinase domain of *EGFR* gene.[@b3-cmar-8-011]--[@b7-cmar-8-011] The majority of *EGFR* activating mutations are exon 19 deletions (45%) and a point mutation (L858R) in exon 21 (40%--45%).[@b8-cmar-8-011],[@b9-cmar-8-011] Activating *EGFR* mutations are significantly more common in Asians, women, never-smokers, and patients with adenocarcinoma histology.[@b5-cmar-8-011]

The enhanced response to *EGFR* TKIs in patients harboring activating mutations has led major oncology groups to recommend *EGFR* mutation testing to guide therapeutic decision making.[@b10-cmar-8-011]--[@b12-cmar-8-011] However, this molecular assay continues to be underused in clinical practice since it is not always feasible. Moreover, despite the variety of methodologies available for *EGFR* mutation testing,[@b13-cmar-8-011],[@b14-cmar-8-011] there is currently no consensus on the optimal detection method. Traditionally, direct sequencing of DNA, especially the Sanger method, has been regarded as the "gold standard" for *EGFR* mutation testing.[@b15-cmar-8-011] However, this method is limited by its moderate sensitivity, requirement for high-quality tumor samples, and long turnaround time (TAT).[@b16-cmar-8-011],[@b17-cmar-8-011] The drawbacks of direct sequencing and recent advances in molecular techniques have led to the development of commercialized test kits with improved sensitivity and TAT for detecting mutations, such as the Therascreen^®^ EGFR RGQ PCR kit (Quiagen, Manchester, UK).[@b18-cmar-8-011] Furthermore, sources of tumor material have been another challenging issue in the search for an optimal method for *EGFR* mutation testing. Formalin-fixed, paraffin-embedded tissue (FFPET) specimens account for the majority of diagnostic samples in clinical practice, although the amount of tumor tissue available for mutation testing is generally very limited. Cytology samples, gathered at diagnosis less invasively than tissue samples, could be an alternative source for mutation testing when tumor tissue samples are not available or have a limited content of tumor DNA.[@b19-cmar-8-011]--[@b21-cmar-8-011] Recently, the use of surrogate samples such as serum has also attracted attention for mutation testing considering its less invasive collection than other sampling procedures and its nature as a repeatable source. Indeed, the assessment of *EGFR* mutations in plasma has been demonstrated to be feasible in inoperable NSCLC patients.[@b22-cmar-8-011]

Most of the studies evaluating the predictive role of *EGFR* mutations in NSCLC were carried out in Japan, where the incidence of *EGFR* mutations was high (20%--40%). However, data on the incidence of *EGFR* mutations in Europe, and particularly in Spain, are limited.[@b23-cmar-8-011],[@b24-cmar-8-011] Furthermore, the incidence of *EGFR* mutations could vary among different regions of Spain, given that there is a marked geographical variability of lung cancer,[@b25-cmar-8-011] mainly based on the distribution of risk factors, such as smoking.

The present study was conducted to assess the incidence of *EGFR* mutations in newly diagnosed advanced or metastatic NSCLC patients in the Galician region of Spain and the clinical management and outcome of patients with *EGFR*-positive mutations.

Patients and methods
====================

Study design and patients
-------------------------

This was a multicenter, prospective observational study conducted in nine hospitals in the Galician region of Spain belonging to the Galician Lung Cancer Group (GLCG). The primary endpoint of the study was to estimate the incidence of *EGFR*-positive mutation in patients with advanced or metastatic NSCLC. Secondary endpoints included the type of *EGFR* mutations found in *EGFR*-positive patients, the clinical management of patients carrying *EGFR* mutations, and the concordance between tumor mutation status and serum samples.

All consecutive adult patients (aged ≥18 years) with histologically or cytologically confirmed newly diagnosed advanced or metastatic NSCLC (stage IIIB noncandidate for locoregional therapy or stage IV) and candidates for first-line therapy were prospectively screened for *EGFR* mutations during a 13-month period. Patients were further required to have tumor tissue available (taken from primary tumor or metastatic area), obtained fine-needle aspiration (FNA), bronchoalveolar lavage, bronchial brushing, or pleural fluid cytology. Exclusion criteria included histological evidence of mixed small-cell/large-cell carcinoma.

Written informed consent was obtained from all patients before they were included in the study, as was their permission to use their available tumor and serum samples obtained at diagnosis to perform the *EGFR* mutation analyses. The Independent Ethics Committee of Galicia (SERGAS) approved the study protocol. The study was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and applicable regulatory requirements.

*EGFR* mutation testing was performed in tissue samples (FFPET and fresh tissue specimens) obtained from the original biopsy performed at diagnosis, before any treatment was initiated. In case of lack of tumor tissue, *EGFR* mutation analysis could be performed in cytology samples obtained at diagnosis. In addition, whenever possible, mutation status was determined in serum samples obtained from any routine blood extraction performed before treatment initiation. All samples used for *EGFR* mutation testing were required to be obtained through routine procedures carried out under clinical practice conditions.

The therapeutic strategy could be based on the results of *EGFR* mutation testing; however, physicians' therapeutic decision making was based on their clinical judgment and clinical practice conditions.

Patients with *EGFR*-positive mutations were prospectively followed up until premature withdrawal for any cause (including death) or until 9 months from the inclusion of the last patient in the study, whichever came first, in order to characterize their clinical management. *EGFR* mutational status could be evaluated again in those patients experiencing disease progression who had undergone a biopsy or cytology after disease progression according to routine clinical practice. In addition, whenever possible, *EGFR* mutation testing was also performed in serum samples after disease progression.

*EGFR* gene mutation analysis
-----------------------------

Genomic DNA extraction and *EGFR* mutation testing on available tumor samples (biopsy or cytology specimens) was performed at a central laboratory (University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain). DNA extraction and *EGFR* mutation analysis on plasma samples was carried out at the Galician Public Foundation of Genomic Medicine, Santiago de Compostela Clinic Hospital, Santia (Santiago de Compostela, Spain).

*EGFR* mutation detection in tumor samples was performed using the Therascreen^®^ EGFR RGQ PCR kit (Qiagen), a European Conformity (CE) in vitro diagnostic-marked allele-specific real-time polymerase chain reaction test designed to detect 29 somatic mutations in exons 18, 19, 20, and 21 of the *EGFR* gene in NSCLC. This certified commercialized test kit is based on mutation-specific amplification achieved using the amplification and refractory mutation system (ARMS) and Scorpions^®^ polymerase chain reaction technologies for detection of amplification.

FFPET and cytology specimen preparation and DNA extraction were previously performed using the DNA FFPE Tissue Kit (Qiagen), following the manufacturer's instructions. Briefly, genomic DNA was derived from tumor tissue after macrodissection at 4 μm of FFPET blocks and fresh tissue specimens. The tumoral region had previously been located in biopsy sections stained with hematoxylin--eosin or in Diff-Quick or Papanicolaou-stained cytologic preparation. Laser microdissection of the tumor tissue was required in case of samples with low tumor cell content. After paraffin removal (xylene 5 minutes, ethanol 5 minutes), tumor tissue sections were lysed by incubation at 56°C with protein kinase K and binding buffer. Subsequently, isopropanol was added to the lysis mixture and the resulting mixture was centrifuged through a column with a glass fiber filter insert. The adsorbed DNA was washed and then eluted from the column with an aqueous solution. The amount of genomic DNA was quantified by spectrophotometry (NanoDrop ND-1000 instrument; Thermo Fisher Scientific, Waltham, MA, USA) and adjusted to a fixed concentration to be added to the amplification/detection mixture of the Therascreen^®^ EGFR RGQ PCR kit. Target DNA amplification and *EGFR* mutations detection was performed using the ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). A mutant control and a negative control were used to confirm the validity of each run. Data analysis and reporting of results were fully automated.

Free-circulating DNA from serum was purified using the QIAamp Circulating Nucleic Acid Kit and the QIAvac 24 Plus (both from Qiagen) following the manufacturer's instructions. Detection of *EGFR* mutations in serum samples was also carried out using the Therascreen^®^ EGFR RGQ PCR kit. The analysis was performed according to the manufacturer's instructions, and the reactions were run in the Rotor-Gene Q 5plex HRM instrument and analyzed with the Rotor-Gene Q software (version 2.0.2) (Qiagen). Following the manufacturer's instructions, Rotor-Gene Q plots from all reactions were checked in order to avoid false positives due to linear increase in fluorescence (which arises due to a fluorescence artifact). After inspection, three samples classified as negative (under the ΔCt cutoff values defined by the manufacturer to identify mutations from FFPET) demonstrated an exponential increase in fluorescence (which is characteristic of true positives). The increase of ΔCt cutoff values by 20% allowed these three samples to be classified as positives. No other changes in mutation status for the remaining samples (N=193) were observed after increasing the ΔCt cutoff values. The three potentially positive samples by serum analyses (after increasing ΔCt cutoff values by 20%) were confirmed as positives when results from FFPET and serum were merged (until then, results from each study were blind to the other).

*EGFR* mutation status was considered positive when the *EGFR* mutation testing result was positive in at least one of the samples analyzed in each patient. In the event that one of the samples available was negative for *EGFR* mutation and the mutational status was unknown for the other one, *EGFR* mutation status was identified as negative.

Statistical analysis
--------------------

The TAT was calculated from the date the sample was sent to the laboratory until the results obtained were received by the physicians. The association between *EGFR* mutation status and clinical characteristics was calculated using the chi-square test or the Fisher's exact test. *EGFR* mutation rate between tumor and serum samples was compared by the chi-square test, and the concordance of the mutation rate between tumor (biopsy or cytology) and serum specimens was estimated using Cramer's *V* coefficient, where coefficient values closer to 1 indicate a stronger concordance. The sensitivity and specificity of the detection of *EGFR* mutations in serum specimens with respect to tumor samples were estimated. Positive predictive value (PPV) and negative predictive value were also assessed.

Efficacy analyses were conducted on the patients who had tumors carrying *EGFR* mutations. Tumor response was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.[@b26-cmar-8-011] The probability of progression-free survival (PFS) and overall survival (OS) was estimated using the Kaplan--Meier method. PFS was assessed from the start of therapy for NSCLC until documented disease progression or death from any cause. Patients were censored at the date of last follow-up if still alive or without disease progression at the time of the analysis. OS was measured from the start of treatment to death. Patients were censored at the date of last follow-up if still alive at the time of the analysis.

The statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) version 17.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients
--------

From February 2011 to March 2012, a total of 209 patients from nine Spanish centers were enrolled in the study. Eleven patients were excluded for not fulfilling the inclusion criteria. Therefore, a total of 198 patients were prospectively screened for *EGFR* mutations. The patient and sample disposition flow diagram is shown in [Figure 1](#f1-cmar-8-011){ref-type="fig"}. The demographic and clinical characteristics of these patients are shown in [Table 1](#t1-cmar-8-011){ref-type="table"}. Briefly, 34% were female, all but one patient was Caucasian, and 22% were never-smokers. The most common histology was adenocarcinoma (69%). Eastern Cooperative Oncology Group (ECOG) Performance Status was 0 or 1 in 68% of patients.

*EGFR* mutation status and clinical characteristics
---------------------------------------------------

Of the 198 tumor samples available, *EGFR* mutation analyses were performed on 114 (58%) tumor samples gathered from the biopsy performed at diagnosis (112 from FFPET and two from fresh tissue blocks) and on 84 (42%) cytology specimens ([Figure 1](#f1-cmar-8-011){ref-type="fig"}). Cytology specimens were mainly obtained through FNA (63%). The source and type of tumor samples for *EGFR* mutation testing are shown in [Table 2](#t2-cmar-8-011){ref-type="table"}.

*EGFR* mutation testing could not be performed in the tumor samples of six (3%) patients due to a too-low content of tumor cells in the tissue sample. In addition, the results of *EGFR* mutation analysis could not be evaluated in seven (3.5%) patients because of insufficient DNA quality. *EGFR* mutation data for 184 (93.4%) patients could be assessed ([Figure 1](#f1-cmar-8-011){ref-type="fig"}). Of these, 25 (13.6%) had *EGFR* mutations, whereas 159 (86.4%) patients were negative for *EGFR* mutation. Of the 25 patients with *EGFR* mutations, 15 (60%) underwent mutation analysis performed on FFPET samples and ten (40%) on cytology specimens. Among patients carrying *EGFR* mutations, 22 (84%) had sensitizing mutations: 44% had exon 19 deletion and 44% exon 21 L858R point mutation ([Table 3](#t3-cmar-8-011){ref-type="table"}). The median TAT was 8 (6--13) days.

*EGFR* mutation assessment in serum samples was performed in 196 patients. Of these, 174 patients also had tumor sample results (88.8% of patients with tumor results), of whom 14 (8.1%) had *EGFR* mutations. Of patients harboring *EGFR* mutations, seven (50.0%) patients had exon 21 L858R mutation and five (35.7%) patients had exon 19 deletion ([Table 3](#t3-cmar-8-011){ref-type="table"}).

There was a significant association between *EGFR* mutation status in tumor samples and serum specimens (*P*\<0.001). The Cramer's *V* coefficient used to assess the overall concordance between the tumor and serum specimens was 0.6. The specificity of serum *EGFR* mutation testing with respect to tumor mutation status was 99%, whereas the sensitivity was 52%. The PPV and negative predictive value were 93% each ([Table 4](#t4-cmar-8-011){ref-type="table"}).

*EGFR* mutation status between baseline and disease progression could not be performed, given that tumor samples were not obtained at progression due to the refusal of patients to undergo the biopsy or because physicians did not consider the biopsy necessary.

*EGFR* mutations were more frequently detected in female sex (68%) (*P*\<0.001), patients who had never smoked (68%) (*P*\<0.001), and those with an adenocarcinoma (100%) (*P*\<0.01) ([Table 1](#t1-cmar-8-011){ref-type="table"}). Histological confirmation (biopsy) of NSCLC had been performed in 16 (64%) patients, whereas in ten (40%) patients, the diagnosis was confirmed by cytology (FNA). All but one patient had stage IV NSCLC. Local/regional (40%) and pleural (40%) metastases followed by bone (24%) and brain (20%) metastases were mainly found in patients with *EGFR* mutations.

Treatment
---------

The mean time from diagnosis of advanced or metastatic disease to treatment initiation was 1.2±0.5 months. All but two patients received first-line treatment and the two remaining patients were given best supportive care after mutation testing results were available. Gefitinib was administered as monotherapy in 21 (87.5%) patients and in combination with carboplatin in one patient. Only one patient received chemotherapy plus biological therapy (cisplatin + docetaxel + bevacizumab).

Among patients who received gefitinib, ten (47.6%) patients had tumors containing *EGFR* mutations in exon 21, nine (42.9%) in exon 19, and two (9.5%) in exon 20. Gefitinib was administered in combination with carboplatin in one patient harboring an *EGFR* mutation in exon 19 and chemotherapy plus bevacizumab was given to one patient with an exon 21 mutation.

Efficacy
--------

Efficacy analyses were conducted in those patients harboring *EGFR* mutations who had received first-line therapy (n=23). Three patients were lost to follow-up; therefore, a total of 20 patients had available data for efficacy evaluation.

The overall response rate (ORR) was 60.9%. Partial response was attained in 14 (60.9%) patients, disease stabilization was achieved in two patients (8.7%), and four patients (17.4%) showed disease progression during treatment. The ORR for those patients with *EGFR*-sensitizing mutations (exon 19 deletion and exon 21 L858R mutation) who received gefitinib (n=17) was 70.6%. Among these patients, two (11.8%) reached disease stabilization (≥12 weeks) and three had progressive disease.

The median duration of follow-up was 9.7 (range: 4.5--15.8) months. The median PFS was 9.7 (95% confidence interval \[CI\]: 4.0--15.5) months for patients receiving first-line treatment (n=20) and the 1-year PFS rate was 37% ([Figure 2A](#f2-cmar-8-011){ref-type="fig"}). The median PFS was 9.7 (95% CI: 4.3--15.1) months for patients treated with gefitinib monotherapy (n=18) and 10.0 (95% CI: 4.8--15.3) months for those patients receiving gefitinib monotherapy and carrying *EGFR*-sensitizing mutations (n=17). The median OS was 17.8 (95% CI: 7.3--28.3) months and the 1-year survival rate was 63% ([Figure 2B](#f2-cmar-8-011){ref-type="fig"}). The median OS for those patients harboring *EGFR*-sensitizing mutations who received gefitinib monotherapy was 17.8 (13.9--21.6) months. At the time of the analysis, nearly half of the patients (12 out of 25) were alive. Half of the patients who died harbored *EGFR* mutations in exon 19, five patients carried a mutation in exon 21, and the remaining two patients had a mutation in exon 20. Fifteen (60%) patients withdrew prematurely from the study, mainly due to death (67%).

Therapy after disease progression
---------------------------------

Of the 23 patients who received first-line treatment, eight (34.8%) patients were administered second-line chemotherapy after disease progression. Second-line regimens included pemetrexed, used as monotherapy (four patients) or in combination with cisplatin (three patients), and erlotinib (one patient).

Discussion
==========

The present study found that 13.6% of newly diagnosed patients with advanced NSCLC in the Galician region of Spain carried *EGFR* mutations. Moreover, our data support the efficacy and safety of first-line gefitinib in NSCLC patients with *EGFR* mutation-positive tumors.

The frequency of *EGFR* mutation in our study is consistent with that recently reported in a large European study in a Caucasian population, including Spanish patients with advanced NSCLC (13.7%), wherein the Therascreen^®^ EGFR RGQ PCR kit was also used.[@b23-cmar-8-011] Furthermore, the *EGFR* mutation rate was also similar to that detected using the same kit (14%) in formalin-fixed, paraffin-embedded tumor samples from Spanish patients diagnosed with NSCLC.[@b13-cmar-8-011] However, the mutation rate was lower than that described in the largest Spanish screening for *EGFR* mutations in NSCLC (16.6%),[@b24-cmar-8-011] where the incidence of *EGFR* mutations may have been overestimated, possibly due to the enriched population of women and never-smokers. Additionally, the mutation testing assay applied in this large Spanish study was different from that used in our screening. More recently, a large study conducted in Spain has pointed to an *EGFR* mutation rate of 11.6%, where different mutation analysis methodologies were used for *EGFR* mutation testing.[@b27-cmar-8-011] Despite the differences in sample size, baseline population characteristics, and methodologies used for mutation testing between these national studies and the study presented here, it must be taken into account that this is a regional screening. Hence, the geographical variability in the distribution of risk factors such as smoking or sex may influence *EGFR* mutation rate. We found that *EGFR* mutations were more frequent in women and never-smokers, in line with previous reports in Caucasians.[@b13-cmar-8-011],[@b23-cmar-8-011]

*EGFR* mutation testing was feasible in the majority of patients (95%) evaluated in our study. This finding supports the idea that *EGFR* mutation testing should become a routine procedure to guide therapeutic decision making by physicians in clinical practice. Indeed, major oncology groups, including the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP), have recently recommended *EGFR* mutation testing before treatment initiation.[@b10-cmar-8-011]--[@b12-cmar-8-011],[@b28-cmar-8-011]

In the current investigation, we found that *EGFR* mutation testing was feasible in a similar proportion of tissue and cytology samples using the Therascreen^®^ EGFR RGQ PCR kit. Additionally, the *EGFR* mutation detection rate using this test in cytology samples was comparable to that detected in conventional tumor tissue samples. Our results therefore further strengthen the argument that the use of cytology samples (including FNA and pleural effusion) is an appropriate alternative for *EGFR* mutation testing when tumor tissue samples are not available or have a low content of tumor DNA.[@b20-cmar-8-011],[@b21-cmar-8-011] Indeed, the suitability of cytology samples for routine clinical practice has been recognized in recently published recommendations for *EGFR* mutation testing.[@b16-cmar-8-011]

In an attempt to assess the convenience of serum samples for *EGFR* mutation testing, we found that *EGFR* mutation rates were higher in tumor tissue (13.6% in evaluable samples) than in serum (8.1%) using the Therascreen^®^ EGFR RGQ PCR kit. Compared with matched tumor tissue, the sensitivity and specificity of *EGFR* mutation tests were 52% and 99% for serum samples. Our results are therefore consistent with those recently reported in Caucasian patients (specificity 99.8% and sensitivity 65.7%) using, as in the study reported here, the Therascreen^®^ EGFR mutation kit.[@b23-cmar-8-011] Though the moderate sensitivity of *EGFR* testing seen in serum could recommend against the use of serum samples rather than tissue specimens, the significant concordance and the high specificity and PPV could point to the use of serum as a suitable option in patients when tumor samples are unavailable. However, although these results, together with previous reports suggesting the convenience of serum samples,[@b29-cmar-8-011]--[@b31-cmar-8-011] are promising, tumor samples should be considered the preferred sample source when available until there is evidence for a higher mutation detection rate using a specific kit for serum samples.

In addition to the requirement for a small amount of testing material, an optimal diagnostic test should offer an accurate result in as short a time as possible to avoid delays in treatment initiation. The median TAT of 8 days to establish the *EGFR* mutation status using the commercial Therascreen^®^ kit would allow physicians to have available information for treatment individualization in a very short period of time after diagnosis. This is an important concern, as the majority of patients with NSCLC present with advanced or metastatic disease at diagnosis and therefore require prompt initiation of targeted therapy.

More than 90% of patients received first-line treatment with TKIs after the results of *EGFR* mutation status were available. All of them received gefitinib since it was the only *EGFR* TKI approved in Europe at the time when the study was conducted. As a descriptive comparison only, the PFS achieved in this study (9.7 months) was comparable to that previously described in the clinical trials carried out with gefitinib in Asian patients with advanced NSCLC.[@b3-cmar-8-011],[@b32-cmar-8-011] Moreover, our results are consistent with the PFS (9.7 months) and the OS (19.2 months) data reported in the only study of first-line gefitinib conducted in the European population of Caucasian patients with advanced NSCLC harboring *EGFR* mutations.[@b23-cmar-8-011] The ORR achieved in our *EGFR* mutation-positive NSCLC population (70.6%) is comparable to that previously shown in Asian patients carrying *EGFR* mutations treated with gefitinib (62% and 74%)[@b3-cmar-8-011]--[@b5-cmar-8-011] and similar to that described in Caucasian patients harboring activating sensitizing *EGFR* mutations (69.8%).[@b23-cmar-8-011] In summary, taken together with recent findings,[@b23-cmar-8-011] the efficacy results of the current study suggest the benefit in terms of response and survival of first-line gefitinib in Caucasian patients.

The interpretation of our data should take into account the limitations of this study arising from its regional nature and the limited sample population. This study is limited to a geographical region in Spain and may not reflect the incidence of *EGFR* mutation in NSCLC in the general population of the country. However, regional data could provide interesting information about the incidence of *EGFR* mutations considering the geographical variability of lung cancer in Spain regarding risk factors such as smoking or sex and some environmental factors. Therefore, despite the obvious limitations of the study, our findings, though modest, might provide a welcome addition to the limited data available on *EGFR* mutation incidence in a Spanish population with advanced NSCLC and on treatment patterns and clinical outcome of patients carrying *EGFR* mutations.

Conclusion
==========

The incidence of *EGFR* mutations in Galicia is consistent with the data previously reported in Spain. Moreover, our results confirm that *EGFR* mutation testing is a feasible diagnostic platform to guide therapeutic decision making in NSCLC patients in routine clinical practice using tumor tissue or cytology samples. It was also found that serum samples could be considered if tumor specimens are unavailable or tumor DNA is insufficient. Finally, these findings support that first-line gefitinib is effective in Caucasian patients with NSCLC carrying *EGFR* mutations.
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![Patient and sample disposition flow diagram.\
**Abbreviations:** NSLC, non-small-cell lung cancer; *EGFR*, epidermal growth factor receptor.](cmar-8-011Fig1){#f1-cmar-8-011}

![Kaplan--Meier curves for PFS (**A**) and OS (**B**) in patients with advanced or metastatic NSCLC carrying *EGFR* mutations.\
**Abbreviations:** CI, confidence interval; OS, overall survival; PFS, progression-free survival.](cmar-8-011Fig2){#f2-cmar-8-011}

###### 

Patient demographic and clinical characteristics

  -----------------------------------------------------------------------------------------------------
  Characteristics                 Total\        *EGFR* mutation status (n=184)                 
                                  (n=198)                                                      
  ------------------------------- ------------- -------------------------------- ------------- --------
  Median age (range), years       66 (59--76)   72 (34--85)                      65 (38--84)   NS

  Sex, n (%)                                                                                   

   Male                           151 (76.3)    8 (5.7)                          132 (94.3)    ,0.001

   Female                         47 (23.7)     17 (38.6)                        27 (61.4)     

  Race, n (%)                                                                                  

   Caucasian                      197 (99.5)    25 (13.7)                        158 (86.3)    

   Black                          1 (0.5)       0 (0.0)                          1 (100)       

  Smoking history, n (%)                                                                       

   Former smoker                  90 (45.5)     6 (7.1)                          79 (92.9)     ,0.001

   Current smoker                 65 (32.8)     2 (3.4)                          57 (96.6)     

   Never-smoker                   43 (21.7)     17 (42.5)                        23 (57.5)     

  ECOG PS, n (%)                                                                               

   0                              27 (13.6)     2 (8.7)                          21 (91.3)     

   1                              106 (53.5)    15 (14.7)                        87 (85.3)     

   2                              49 (24.7)     5 (11.2)                         40 (88.8)     

   ≥3                             16 (8.1)      3 (21.4)                         11 (78.6)     

  Tumor histology, n (%)                                                                       

   Adenocarcinoma                 136 (68.7)    25 (100)                         101 (80.2)    ,0.01

   Squamous-cell carcinoma        43 (21.7)     0 (0.0)                          41 (100)      

   Large-cell carcinoma           16 (8.1)      0 (0.0)                          14 (100)      

   Adenosquamous-cell carcinoma   2 (1.0)       0 (0.0)                          2 (100)       

   Carcinoma NOS                  1 (0.5)       0 (0.0)                          1 (100)       
  -----------------------------------------------------------------------------------------------------

**Abbreviations:** ECOG PS, Eastern Cooperative Oncology Group Performance Status; *EGFR*, epidermal growth factor receptor; NOS, not otherwise specified; NS, not significant.

###### 

Source and type of tumor samples for *EGFR* mutation testing (n=198)

  Sample characteristics                             N (%)
  -------------------------------------------------- ------------
  Biopsy                                             114 (57.6)
  Tumor tissue source                                
   Primary tumor                                     90 (78.9)
   Metastatic sites                                  24 (21.1)
  Biopsy sample type                                 
   FFPET                                             112 (98.2)
   Fresh tissue                                      2 (1.8)
  Cytology                                           84 (71.4)
  Tumor tissue source                                
   Primary tumor                                     60 (71.4)
   Metastatic sites                                  24 (28.6)
  Cytology type                                      
   FNA                                               53 (63.1)
   Bronchoalveolar lavage                            10 (11.9)
   Bronchial brushing                                6 (7.1)
   Pleural effusion                                  6 (7.1)
   Other[a](#tfn2-cmar-8-011){ref-type="table-fn"}   9 (10.7)

**Note:**

Other cytology types used in two or less patients.

**Abbreviations:** *EGFR*, epidermal growth factor receptor; FFPET, formalin-fixed, paraffin-embedded tissue; FNA, fine-needle aspiration.

###### 

Type of *EGFR* mutations identified in tumor (N=25) and serum samples (N=14)

  Type of mutations   Tumor sample   Serum sample
  ------------------- -------------- --------------
  Exon 18             0 (0)          0 (0)
  Exon 19             11 (44)        5 (35.7)
   Del 19             11 (44)        5 (35.7)
  Exon 20             2 (8)          1 (7.1)
   Insertion          1 (4)          1 (7.1)
   Not specified      1 (4)          --
  Exon 21             12 (48)        8 (57.1)
   L858R              11 (44)        6 (42.9)
   L861Q              1 (4)          1 (7.1)

**Abbreviation:** *EGFR*, epidermal growth factor receptor.

###### 

Concordance analysis between tumor and serum samples regarding *EGFR* mutation rate (N=174)

                                                           Tumor sample        
  -------------------------------------------------------- -------------- ---- -----
  Serum sample[a](#tfn5-cmar-8-011){ref-type="table-fn"}                       
   *EGFR* MND                                              148            12   160
   *EGFR* MD                                               1              13   14
   Total                                                   149            25   174
   *P*-value[b](#tfn6-cmar-8-011){ref-type="table-fn"}     \<0.001             

**Notes:**

Increasing the detection cutoff by 20%;

chi-square test. Concordance rate =92.5%; overall concordance (Cramer's *V* coefficient) =0.6; specificity =99.3%; sensitivity =52.0%; positive predictive value =92.9%; negative predictive value =92.5%.

**Abbreviations:** MD, mutation detected; MND, mutation not detected; *EGFR*, epidermal growth factor receptor.
